Lexaria Bioscience Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Lexaria Corp. (Lexaria Bioscience Corp.) on September 9, 2009. The registrant is incorporated in Nevada and maintains its principal address in Vancouver, British Columbia, Canada. The report primarily addresses corporate governance changes rather than financial performance.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report does not contain financial statements or quantitative financial data.
Material Changes
The material change reported is the appointment of a new Director to the Company's Board.
- Item 5.02: On September 9, 2009, Dr. David DeMartini was appointed as a Director.
- Background: Dr. DeMartini is an expert in geophysical fields, specifically seismic "bright spot" data analysis. He previously held senior positions at the Shell Bellaire Research Center (1980–1998) and holds a Ph.D. in Physics from The Ohio State University.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future guidance, outlook, specific risks, contingencies, or unusual items. It includes a reference to a News Release dated September 10, 2009, as an exhibit, but the content of that release is not included in the provided text.
Key Facts for Investor Verification
- Verify the full text of the News Release dated September 10, 2009 (Exhibit 99.1) for additional context on the appointment.
- Confirm the current composition of the Board of Directors following Dr. DeMartini's appointment.
- Review the most recent 10-K or 10-Q filings for actual financial performance data, as this 8-K contains none.